Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
World game at war: why some European nations have threatened a World Cup boycott 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
(4) - EconoTimes)
STAMFORD, Conn., May 07, 2018 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that between April 23, 2018 and May 7, 2018, the Compensation Committee of Loxo Oncology’s Board of Directors granted non-qualified stock options to purchase an aggregate of 98,525 shares of its common stock to thirteen new employees. The options were granted as an inducement material to the employees’ acceptance of employment with Loxo Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
Each option has an exercise price equal to the closing price of Loxo Oncology’s common stock on the day of grant. Each option will vest and become exercisable as to 25% of the shares on the first anniversary of the recipient’s start date, and will vest and become exercisable as to the remaining 2.08333% of the shares in 36 equal monthly installments following the first anniversary, in each case, subject to each such employee’s continued employment with Loxo Oncology on such vesting dates.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Lauren Cohen
Director, Corporate Communications
[email protected]
Investors:
Peter Rahmer
Endurance Advisors, LLC
415-515-9763
[email protected]
Media:
Dan Budwick
1AB Media
973-271-6085
[email protected]
